Market Overview

UPDATE: Citigroup Reiterates Neutral Rating, Raises PT on Allscripts Healthcare Solutions

Related MDRX
Cookeville Medical Center Selects Allscripts for Chronic Care Management (CCM) Program
Allscripts Partners With CoverMyMeds to Help Patients Fill Prescriptions Faster

In a report published Wednesday, Citigroup reiterated its Neutral rating on Allscripts Healthcare Solutions (NASDAQ: MDRX), and slightly raised its price target from $10.50 to $11.00.

Citigroup noted, “We believe Allscripts faces significant challenges on the product development and sales execution fronts, but many of these challenges are priced into the stock. We are modestly raising our 2012 and 2013 EPS estimates on the company's recent aggressive repurchase of shares. We are not yet ready to get more positive on the shares, but could be in a position to do so if we believe the company can fix its operational issues and restore faith to its customer base.”

Allscripts Healthcare Solutions closed Tuesday at $9.79.

Latest Ratings for MDRX

Sep 2015Canaccord GenuityInitiates Coverage onBuy
Aug 2015Argus ResearchUpgradesHoldBuy
Jun 2015OppenheimerInitiates Coverage onPerform

View More Analyst Ratings for MDRX
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings


Related Articles (MDRX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters